Price movement over the last 24 hours
ADMA Biologics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $54.7. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QCLN | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $68.47 |
52-Week Low | $7.60 | $34.04 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
QCLN trades at $58.70, up 3.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed sentiment amid clean energy sector volatility, with support at $55 and resistance at $60. Recent news highlights policy risks from stalled US permits and geopolitical tensions affecting solar supply chains, while global investment in renewables continues to grow.
Outlook remains cautious due to regulatory headwinds and cost pressures, though long-term clean energy demand provides upside potential. Key risks include US-China trade policies and inflation-driven installation costs, with investor sentiment divided between near-term challenges and structural growth opportunities.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →